TMCnet News
DBV Technologies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the underwriters for its previously announced global offering reserved to specified categories of investors have exercised in full their option to purchase 1,368,667 additional ordinary shares in the form of 2,737,334 American Depositary Shares (“ADSs”), at an offering price of $6.59 per ADS, before deducting commissions and estimated offering expenses (the “Option”). Each ADS represents the right to receive one-half of one ordinary share, and the offering price of $6.59 per ADS corresponds to a price of €12.04 per ordinary share (on the basis of an exchange rate of $1.0945 = €1.00). The closing of the Option is expected to occur on October 15, 2019, subject to customary closing conditions. Consequently, following exercise of the Option, the total number of ordinary shares sold in the global offering is 10,852,733 ordinary shares, including 9,283,289 ordinary shares in the form of 18,566,578 ADSs, bringing the total gross proceeds from the global offering to approximately $143.0 million (approximately €130.7 million). Goldman Sachs and Citigroup are acting as joint lead book-running managers for the global offering. JMP Securities, H.C. Wainwright & Co. and Bryan, Garnier & Co are acting as co-managers for the global offering. No stabilization activity has been undertaken and the stabilization period is now closed. The Company plans to use the net proceeds from the global offering, together with its existing cash and cash equivalents, primarily to prepare for the commercialization of Viaskin Peanut, if approved, as well as to advance development of the Company’s other product candidates and for working capital and general corporate purposes. A registration statement on Form F-3 relating to the securities to be issued in the global offering was filed with the Securities and Exchange Commission and was declared effective on October 1, 2019. The offering of ordinary shares in the form of ADSs was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, as well as a free writing prospectus related to the global offering. A free writing prospectus, final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the Securities and Exchange Commission and is available on the Securities and Exchange Commission’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained for free from: Goldman Sachs, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: 1-866-471-2526, facsimile: 212-902-9316 or via email: [email protected]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or via telephone: 800-831-9146. Application was made to list the new ordinary shares to be issued pursuant to the global offering on the regulated market of Euronext Paris pursuant to a listing prospectus which received the approval of the Autorité des Marchés Financiers ("AMF") on October 9, 2019 under number19-485, and comprising (i) the 2018 universal registration document, including the risk factors, filed with the AMF on October 9, 2019 under number D.18-0889 (document d’enregistrement universel 2018), which incorporates by reference the 2018 registration document (document de référence 2018) and the 2019 half-year financial report (rapport financier semestriel 2019), and (ii) a Securities Note (Noted’opération), including (iii) a summary of the prospectus. Copies of the Company’s 2018 universal registration document are available free of charge at the Company’s head office located at: 177-181 avenue Pierre Brossolette – 92120 Montrouge – France. The listing prospectus will be published on the AMF’s website at www.amf-france.org. * * * About DBV Technologies Forward Looking Statements DBV Investor Relations Contact Disclaimers The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions. A French listing prospectus comprising (i) the Company’s universal registration document, filed with the AMF on October 9, 2019 under number D.18-0889, (ii) a securities note (including the summary) relating to the admission to trading of the Company’s new shares on Euronext Paris and (iii) the summary of the French listing prospectus was submitted for approval by the AMF and will be published on the AMF’s website at www.amf-france.org. Copies of the Company’s universal registration document, including the risk factors, are available for free at the Company’s head office located at: 177-181 avenue Pierre Brossolette – 92120 Montrouge – France and on the AMF’s website at www.amf-france.org. This document does not constitute an offer to the public in France and the securities referred to in this document can only be offered or sold in France pursuant to article L. 411-2-II of the French Monetary and Financial Code to (i) providers of third party portfolio management investment services, (ii) qualified investors (investisseurs qualifiés) acting for their own account and/or (iii) a limited group of investors (cercle restreint d’investisseurs) acting for their own account, all as defined in and in accordance with articles L. 411-1, L. 411-2 and D. 411-1 to D. 411-4 and D. 754-1 and D. 764-1 of the French Monetary and Financial Code. This announcement is not an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (the “Prospectus Regulation”). With respect to the member States of the European Economic Area, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State. As a result, the securities may not and will not be offered in any relevant member State except in accordance with the exemptions set forth in Article 1 (4) of the Prospectus Regulation or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Regulation and/or to applicable regulations of that relevant member State. This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
Attachment |